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Ghrelin, a natural ligand for the growth hormone (GH)-secretagogue receptor 
(GHS-R), is now known to play a role in a number of different physiological processes. 
For example, ghrelin increases GH secretion, feeding, and body weight when 
administered centrally or peripherally. These unique effects of ghrelin should be 
invaluable for the development of novel treatments and disease diagnostic techniques. 
Clinical trials have already been performed to assess the utility of ghrelin for the 
treatment of several disorders including anorexia, cachexia, and GH-related disorders. 





   Ghrelin is a peptide hormone that was discovered in 1999 as an endogenous ligand 
for the growth hormone (GH)secretagogue receptor (GHS-R) [1]. Ghrelin is a 28-
amino-acid peptide and possesses a unique fatty acid modification, n-octanoylation, at 
Ser 3. There are two circulating forms of ghrelin, acylated and unacylated (desacyl), and 
the acylated form is essential for ghrelin’s biological activity through GHS-R. Recently, 
however, desacyl ghrelin was reported to influence both cell proliferation and 
adipogenesis through another unknown receptor [2-5]. Ghrelin is produced primarily in 
the stomach and circulates in the blood at a considerable plasma concentration. 
Expression of ghrelin is also detectable in the hypothalamus, intestine, pituitary, 
placenta, and other tissues [1, 6-8]. Ghrelin is now known to play a role in a number of 
different physiological processes; for example, ghrelin increases GH secretion and 
feeding, and decreases insulin secretion [1, 9-19].  
These unique effects of ghrelin and growth hormone secretagogues (GHS) should 
be invaluable for the development of novel treatments and disease diagnostic techniques 
[20-22]. Clinical trials have already been performed to assess the utility of ghrelin for 
the treatment of various disorders including anorexia [23-26], cachexia [27-29], 
malnutrition [30], GH-related disorders [31], and postgastrectomy/esophagectomy [32, 
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33]. Because many excellent reviews concerning basic and clinical research on ghrelin 
have already been published, we will summarize and discuss recent clinical trials of 
ghrelin in this work. 
 
2. Physiological actions of ghrelin 
2. 1. Orexigenic action  
   Ghrelin has a well-established role in stimulating appetite and increasing food 
intake [34, 35]. Peripheral administration of ghrelin stimulates GH secretion and 
appetite in both animals and humans [10, 18]; it is the only hormone known to have this 
effect. Ghrelin increases c-fos expression in the arcuate nucleus, and also activates 
hypothalamic neuropeptide Y (NPY)/Y1 receptors and agouti-related peptide (AgRP) 
pathways [36-38]. In addition, ghrelin induces food intake via the orexin pathway [39]. 
These functions are mediated at least in part by vagal nerve pathways [40]. Repeated 
administration of ghrelin resulted in significant weight gain in rats [41] and patients 
with chronic obstructive pulmonary disease (COPD) [28].  
2. 2. Stimulation of GH secretion 
   Ghrelin strongly stimulates GH secretion in humans [12, 16, 17, 42], several-fold 
more potently than GHRH under similar conditions. Furthermore, ghrelin and growth 
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hormone releasing hormone (GHRH) synergistically increase GH release [17]. Ghrelin 
might also play a role in GH release in a non-acute setting [43, 44]. GH regulates IGF-I 
levels, promotes anabolism, and increases muscle strength [45, 46]. While GH enhances 
lipolysis, IGF-1 stimulates protein synthesis, myoblast differentiation, and muscle 
growth.  
2. 3. Anti-inflammatory action 
   Evidence that ghrelin exerts anti-inflammatory actions has been accumulating. 
Ghrelin suppresses the production of proinflammatory cytokines, including IL-1, IL-6, 
and TNF- both in vitro [47, 48] and in vivo [49-51]. In clinical trials, daily 
administration of ghrelin for three weeks decreased inflammatory cytokine levels and 
neutrophil density in sputum from patients with chronic respiratory infections [52]. In 
contrast, ghrelin induces the anti-inflammatory cytokine IL-10 [49, 53]. 
     Ghrelin inhibits the activation of NF-B, a transcription factor known to control 
the production of multiple pro-inflammatory cytokines during inflammatory insults [48, 
50, 53]. Although the molecular mechanisms and cellular targets mediating ghrelin 
inhibition of NF-B activation remain to be determined, the vagus nerve may play an 
important role in the ghrelin-mediated inhibition of pro-inflammatory cytokine release 
[50, 54]. Cachexia and muscular wasting occur via protein degradation by the 
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ubiquitinproteasome pathway [55]. Two muscle-specific ubiquitin ligases, muscle 
RING-finger protein-1 (MuRF1) and atrogin-1/muscle atrophy F-box (MAFbx), are up-
regulated under catabolic conditions. NF-B activation may regulate skeletal muscle 
proteasome expression and protein degradation. The elevation in MuRF1 and MAFbx 
expression seen in skeletal muscle after thermal injury, arthritis, and dexamethasone 
administration were normalized, attenuated, and prevented, respectively, by ghrelin or 
GHS administration [56-58]. IGF-1 prevents the expression of MuRF1 and MAFbx by 
inhibiting Forkhead box O (FOXO) transcription factors via stimulation of the 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway. The IGF-1 receptor triggers 
activation of several intracellular kinases, including phosphatidylinositol-3-kinase 
(PI3K) [59]. Thus, the effects of ghrelin on NF-B activation and IGF-1 synthesis are 
favorable for minimizing inflammatory responses and sarcopenia in patients with 
cachexia. 
2.4. Other actions 
    The role of ghrelin in stimulating gastric emptying and acid secretion is well-
established [60]. This effect may ameliorate gastrointestinal symptoms in patients with 
anorexiacachexia syndrome. Ghrelin also increases endogenous nitric oxide (NO) 





3. Potential clinical applications of ghrelin 
3.1. Appetite-related disorders 
3.1.1. Anorexia nervosa (AN) and related disorders  
     Anorexia nervosa (AN) is an eating disorder characterized by chronically 
decreased caloric intake, resulting in self-induced starvation. Plasma ghrelin levels are 
elevated in lean patients with anorexia nervosa, consistent with a state of negative 
energy balance [65-67]. Only a few preliminary studies have been performed to 
examine the effects of ghrelin in individuals with AN. Miljic et al. infused ghrelin (300-
min intravenous infusion of 5 pmol/kg/min ghrelin) into nine AN patients with very low 
body weights, six AN patients who had partially recovered their body weights but who 
remained amenorrheic, and ten constitutionally thin female subjects [68]. The fifteen 
AN patients felt significantly less hungry compared with the constitutionally thin 
subjects, suggesting that AN patients are less sensitive to the orexigenic effects of 
ghrelin than healthy controls. In another paper, however, six of nine patients with 
restrictive AN were reported to have been hungry after ghrelin administration (1.0 
µg/kg as an intravenous bolus), a similar ratio to that seen in normal subjects (five of 
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seven) [69]. We examined the effects of ghrelin on appetite, food intake, and nutritional 
parameters in AN patients [26]. Five female patients who met the Diagnostic and 
Statistical Manual IV (DSM-IV) criteria for restricting-type AN [70] and desired to 
recover from the disorder participated in this study.  The patients were hospitalized for 
26 days (6 days pre-treatment, 14 days ghrelin infusion, and 6 days post-treatment). The 
patients received an intravenous infusion of 3 g/kg ghrelin twice a day (before 
breakfast and dinner). Attitudes toward food were evaluated by visual analogue scale 
(VAS) questionnaires and daily energy intake was calculated by dieticians. Ghrelin 
infusion improved epigastric discomfort or constipation in four patients, whose hunger 
scores on VAS also increased significantly after ghrelin administration. Daily energy 
intake during ghrelin administration increased by 1236% compared with the pre-
treatment period. The change in body weight of the five patients ranged from +1.5 to 
2.4 kg. Nutritional parameters such as total protein and triglyceride levels improved. 
There were no serious adverse effects, including psychological symptoms. All patients 
who did not gain weight during hospitalization did so after discharge. These findings 
suggest that ghrelin may have therapeutic potential in AN patients who cannot gain 
weight because of gastrointestinal dysfunction. Clearly, further studies, including 
randomized controlled trials, are needed to determine whether ghrelin is useful for the 
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treatment of AN.  
     Functional dyspepsia (FD) is a disorder characterized by the presence of chronic 
or recurrent symptoms of upper abdominal pain or discomfort [71]. Although no known 
specific organic abnormalities are present in FD, abnormalities in gastrointestinal 
motility and sensitivity are thought to play a role in a substantial subgroup of patients. 
In addition, some patients suffer from anorexia and body-weight loss. We found that 
levels of plasma acylated, but not desacyl, ghrelin correlated with a subjective symptom 
score in FD patients, suggesting that acylated ghrelin may play a role in the 
pathophysiology of FD [72]. We attempted to evaluate the clinical response to repeated 
ghrelin administration in patients with anorexia caused by functional disorders, such as 
FD and ‘other eating disorders’ or ‘unspecified eating disorders’ [24]. The inclusion 
criteria in this study were subjects who 1) were diagnosed with functional anorexia, 
including FD or other eating disorders with the exception of anorexia nervosa, 2) were 
lean (BMI < 22 kg/m
2
), and 3) exhibit decreased food intake. Subjects received an 
intravenous infusion of ghrelin for 30 minutes twice a day (before breakfast and dinner) 
for two weeks, and we investigated the effects on food intake, appetite, hormones, and 
metabolic parameters. Six patients with FD were enrolled in this study. Ghrelin 
administration tended to increase daily food intake in comparison to levels before and 
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after completion of treatment, but this difference, which was the primary endpoint of the 
study, did not reach statistical significance. Hunger sensation was significantly elevated 
at the end of drip infusion. No severe adverse effects were observed. These results 
suggest that ghrelin administration is safe and that this treatment has stimulatory effects 
on appetite in patients with FD. Further studies remain necessary to confirm the efficacy 
of ghrelin treatment for anorexia-related disorders.  
 
3.1. 2 Cachexia and related disorders 
     A number of trials seeking to utilize ghrelin for the treatment of cachexia have 
recently been performed [73]. These studies have sought to evaluate ghrelin as a 
treatment for patients with cachexia associated with congestive heart failure (CHF), 
COPD, cancer, and End-stage renal disease (ESRD). Cachexia manifests as excessive 
weight loss in the setting of an underlying chronic disease [74], and is typically 
associated with anorexia as a major cause of weight loss. Weight loss and decreased 
appetite are the major causes of morbidity and mortality in patients with 
anorexiacachexia syndrome. There is an immediate need for effective, well-tolerated 
treatments to stimulate appetite [75], prompting several trials to explore the application 
of ghrelin as a treatment for patients with cachexia.  
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3.1. 2 .1. CHF-associated cachexia 
     Ghrelin induces a positive energy balance state through both GH-dependent and -
independent mechanisms and has protective cardiovascular effects [76]. GH treatment 
may be especially useful in a subgroup of patients with cardiac cachexia [77]. Ghrelin 
stimulates food intake, induces adiposity, regulates the central nervous system to 
decrease sympathetic nerve outflow, and inhibits apoptosis of cardiomyocytes and 
endothelial cells in a GH-independent manner. Nagaya et al. investigated the effects of 
ghrelin on cardiac cachexia in 10 patients with CHF [27] (Table 1). Daily administration 
of ghrelin for three weeks increased both food intake and body weight. This study also 
demonstrated improvements in patient exercise capacity, muscle wasting, and left 
ventricular function. Ghrelin treatment also resulted in significantly decreased plasma 
norepinephrine levels. Although this study was neither randomized nor placebo-
controlled, the eight CHF patients who did not receive ghrelin (control group) were 
followed to rule out any time-course effects during hospitalization. None of the 
aforementioned parameters changed in patients with CHF who did not receive ghrelin 
therapy. Further studies will be necessary to identify the pathways involved in this use 
of ghrelin and to determine the best therapeutic strategies for ghrelin use to combat the 
wasting process found in cardiac cachexia patients [77]. Clinical trials are currently 
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attempting to reproduce these data in a double-blind, placebo-controlled fashion. 
3.1. 2 .2. COPD-associated cachexia 
     Patients with COPD often exhibit some degree of cachexia [78], which is an 
independent risk factor for mortality in COPD; GH treatment increases muscle mass in 
such patients. COPD and CHF are both associated with multiple pathophysiological 
disturbances, including anemia and neurohormonal activation [79]. In COPD patients, 
ghrelin exhibits anti-inflammatory effects. Chronic respiratory infections, characterized 
by neutrophil-dominant airway inflammation, lead to end-stage cachexia [80]. The 
cytotoxicity of accumulated neutrophils against bronchial and alveolar epithelial cells 
induces a deterioration of pulmonary function in COPD, resulting in excess energy 
expenditure and weight loss in patients. Intravenous ghrelin treatment for three weeks 
reduced neutrophil counts in sputum samples as well as the volume of sputum, 
suggesting that ghrelin suppressed excess neutrophil influx [52].  
     An open-label pilot study examined the ability of ghrelin to improve cachexia and 
functional capacity in patients with COPD; ghrelin was administered intravenously for 
three weeks to seven cachectic patients with COPD [28]. Repeated ghrelin 
administration significantly increased food intake, body weight, lean body mass, and 
peripheral and respiratory muscle strength. Ghrelin treatment ameliorated exaggerated 
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sympathetic nerve activity, as indicated by marked decreases in plasma norepinephrine 
levels. Subsequently, another placebo-controlled trial demonstrated that ghrelin 
increased both appetite and body weight with an apparent dose-dependent trend towards 
improved physical performance (chair stand score) [81]. A larger clinical trial is 
currently being conducted to confirm these data in a double-blind, placebo-controlled 
fashion. Comparisons of this treatment to current standard medications will be required 
[79]. 
3.1. 2 .3. Cancer cachexia    
     Anorexia is frequently encountered in cancer patients, and is one of the major 
causes of malnutrition and cachexia in this patient population. Ghrelin administration 
resulted in significant increases in weight and food intake in rodent models of cancer-
associated cachexia [82-84]. DeBoer et al. determined that weight gain resulted from a 
reversal in the loss of lean body mass, a critical component of cachexia [82].  
   Several randomized, double-blind placebo-controlled trials have demonstrated the 
efficacy and safety of ghrelin or GHS in patients with cancer-associated cachexia [23, 
25, 85]. Nearry et al. performed a randomized, placebo-controlled, cross-over clinical 
trial to determine whether ghrelin could stimulate appetite in seven cancer patients with 
severe anorexia [23]. Ghrelin infusion resulted in a marked increase in energy intake in 
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comparison to saline-treated controls; all patients in the study demonstrated increased 
food consumption. The meal appreciation score was also higher in ghrelin-treated 
individuals. Strasser et al. detailed a randomized, double-crossover, phase 1/2 study in 
21 patients with advanced cancer [25]. They infused a low or high dose of ghrelin or 
placebo before lunch daily for four days in each course. Nutritional intake and eating-
related symptoms did not differ between the ghrelin- and placebo-treated groups. More 
patients, however, preferred ghrelin to placebo at the middle and end of the study, 
although this finding was not dose-dependent. In contrast to the results of Neary et al., 
this study did not demonstrate any increases in food intake. As the patient 
characteristics and study designs were very different in the two studies, further 
investigation is required. 
     An important concern regarding the use of ghrelin in cancer-associated cachexia 
is that ghrelin may increase the levels of growth factors, such as GH and IGF-1, that 
stimulate tumor growth. Additionally, ghrelin itself may have mitogenic potential. As 
far as we know, no in vivo data has examined the differences in tumor growth following 
ghrelin or GHS treatment. Long-term, large-scale clinical trials are required to 
determine whether ghrelin treatment promotes tumor growth. 
3.1. 2 .4. End-stage renal disease (ESRD) 
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     ESRD is a chronic condition frequently associated with
 
nutritional dysfunction 
[86]. This type of malnutrition is highly resistant to intervention and is a major predictor 
of
 
morbidity and mortality for patients on either peritoneal
 
dialysis (PD) or hemodialysis. 
Wynne et al. sought to determine whether a single injection of ghrelin could enhance 
food intake in patients with evidence of malnutrition receiving maintenance peritoneal 
dialysis [30]. Nine PD patients exhibiting mild to moderate malnutrition were 
subcutaneously administered either ghrelin or a saline placebo in a randomized, double-
blind, cross-over protocol. Ghrelin administration significantly increased mean absolute 
energy intake during the study meals and non-significant increases in energy intake 
were observed over the first 24 h without a subsequent rebound. This research group 
subsequently sought to analyze the efficacy of repeated ghrelin administration in 
malnourished dialysis patients [87] by performing a double-blind randomized cross-
over study of a week of daily subcutaneous ghrelin injections in a group of 12 
malnourished dialysis patients. Ghrelin administration significantly increased appetite, 
with increases in energy intake noted at the first study meal. Persistence of this effect 
throughout the week was confirmed by food diaries and final study meals, indicating 
that daily ghrelin treatment resulted in a sustained positive change in energy balance in 
malnourished dialysis patients. In support of this data, experiments using a 
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nephrectomized rat model of renal cachexia demonstrated that daily treatment for two 
weeks with ghrelin or two GHS agents (BIM-28125 and BIM-28131) resulted in 
increased food intake, improved lean body mass accrual, and decreased circulating 
inflammatory cytokines [88]. Long-term studies are needed to demonstrate efficacy in 
improving appetite, weight gain, lean body mass, and quality of life. 
 
3.2. GH deficiency-related disorders 
     Strong stimulation of GH secretion by ghrelin has been well documented in 
humans [12-16, 21, 42]. As with GHS, ghrelin may be useful for the diagnosis and 
treatment of short stature and GH deficiency. Elderly individuals may be particularly 
suitable candidates for ghrelin treatment, as ageing is associated with progressive 
decreases in GH secretion, appetite, and energy intake [89-92]. This reduced GH 
secretion is called “somatopause” and may be a cause of age-related metabolic and 
physiologic changes including reduced lean body mass and expansion of adipose mass. 
Sarcopenia is associated with functional decline and death. Altered blood lipid profiles 
also favor the development of vascular diseases that may increase overall mortality. The 
age-related reduction in energy intake has been termed “the anorexia of aging” and 
predisposes to the development of under-nutrition, which has been implicated in the 
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development and progression of chronic diseases commonly affecting the elderly, as 
well as in increasing mortality. Growth hormone therapy increases IGF-I levels, 
promotes anabolism, and increases muscle strength in healthy elderly individuals, as 
well as in selected patient groups [93-95]. Therefore, ghrelin and GHS may also have 
therapeutic potential to assist in the recovery of frail patients who require nutritional 
support and conventional rehabilitation [96]. We evaluated the effects of ghrelin 
administration on physical performance and body composition in patients undergoing 
elective total hip replacement (THR) as treatment for osteoarthritis (OA) in a 
randomized, double-blind, placebo-controlled, phase II study [31]. Thirty-two patients 
were assigned to two groups of 16 subjects each; the ghrelin group received intravenous 
injections of 2 g/kg ghrelin twice daily for three weeks beginning one week before 
surgery, while the placebo group received vehicle alone. While ghrelin significantly 
increased lean body mass after the three-week injection period, it did not affect muscle 
strength or walking ability. Significant decreases in fat mass and GH responses to 
ghrelin injection were also observed. No severe adverse effects occurred in response to 
ghrelin treatment. Despite increased lean tissue reserves, ghrelin administration using 
this study protocol did not provide any favorable effect on physical performance in 
patients with OA undergoing THR. Further studies are necessary to examine the 
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efficacy of ghrelin treatment in such patients. 
     We found that plasma levels of acylated ghrelin in healthy elderly female subjects 
tended to be low and were correlated positively with IGF-1 levels, suggesting that 
negative feedback mechanism does not function properly in elderly subjects [97]. 
Further, acylated ghrelin concentrations in elderly females correlated with both systolic 
blood pressure and the frequency of bowel movements. These findings suggest that, in 
elderly females, acylated ghrelin may play a role in the regulation of the GH/IGF-1 axis, 
blood pressure, and bowel movements.  
 
3.3. Post-gastrectomy and -esophagectomy 
 Body weight loss is common and is a serious outcome in patients who have 
undergone total gastrectomy and esophagectomy. Such weight loss correlates with 
decline in postoperative quality of life and is the most reliable indicator of malnutrition, 
which impairs immune function, susceptibility to infection, and survival [32, 33]. 
Plasma ghrelin levels decreased after total gastrectomy and esophagectomy [65, 98, 99]. 
Moreover, a significant correlation between ghrelin concentration and postoperative 
weight loss suggested a role for loss of ghrelin. To examine this, Adachi et al. evaluated 
the efficacy of ghrelin in 21 patients undergoing total gastrectomy [32]. Food intake and 
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appetite were significantly higher in the ghrelin group (3 g/kg, twice daily for 10 days 
after starting oral food intake following surgery) compared with the placebo group, and 
BW loss was significantly lower in the ghrelin group than in the placebo group. Fat 
mass, lean body mass, and basal metabolic rate decreased significantly in the placebo 
group; however, the reductions in lean body mass and basal metabolic rate were not 
significant in the ghrelin group, although that of fat mass was significant. Thus, short-
term administration of synthetic ghrelin successfully lessened postoperative body 
weight loss and improved appetite and food intake after total gastrectomy. Subsequently, 
the same research group performed a similar study in 20 patients who underwent 
esophagectomy [33]. Again, they found that administration of ghrelin after 
esophagectomy increased oral food intake and attenuated weight loss together with 
maintenance of lean body weight. Thus, ghrelin administration may be useful in 
minimizing the side effects of these operations. 
 
3.4. Other disorders  
     Reflecting the wide expression patterns of both ghrelin and its receptor, this 
peptide is now known to play a role in a number of different physiological processes 
including cellular proliferation and differentiation, pancreatic exocrine and endocrine 
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function, glucose metabolism, sleep and behavior, immune regulation, and 
cardiovascular function. For example, as discussed above, repeated administration of 
ghrelin in patients with CHF significantly improved left ventricular function as well as 
food intake. A large number of studies have been performed by investigators worldwide 
to elucidate the various activities of ghrelin. We believe that some of these may lend 
support to the development of clinical applications of ghrelin to disorders other than 
those described above in the future. 
 
4. Conclusions 
     More than ten years have passed since the discovery of ghrelin, and abundant 
evidence now indicates that it plays a role in a variety of physiological functions. In 
parallel, clinical trials have proceeded to exploit these activities in the treatment and 
diagnosis of human disease. There are several characteristic features of the clinical 
applications of ghrelin: 1) the multiplicity and uniqueness of its function, 2) its unique 
structure and fatty acid modification, and 3) the paucity of severe adverse effects [100]. 
These characteristics should allow us to develop novel and unique therapies for a 
variety of disorders, including many currently intractable and serious diseases. Indeed, 
research on clinical applications of ghrelin is a challenging and potentially rewarding 
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avenue for the future. 
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CHF [27] 2004 open-label pilot study  10 2 μg/kg b.i.d. for
3 wks, i.v.
COPD [28] 2005 open-label pilot study 7 2 μg/kg b.i.d. for
3 wks, i.v.
Cancer cachexia [23] 2004 acute, randomized,
placebo-controlled,
cross-over study
7 5 pmol/kg/min i.v.
for > 180 min
Cancer cachexia [25] 2008 randomized, placebo-
controlled, cross-over
study
21 2 or 8μg/kg, i.v.
for 4 days, once a
day
ESRD [65] 2005 acute, randomized,
placebo-controlled,
cross-over study
9 3.6 nmol/kg, s.c.
ESRD [8] 2009 randomized, placebo-
controlled, cross-over
study
12 12 μg/kg, s.c. for
1 wk, once a day
AN [26] 2009 open-label pilot study 5 3 μg/kg b.i.d. for
two wks, i.v.
FD [24] 2008 open-label pilot study 6 3 μg/kg b.i.d. for
two wks, i.v.
THR for OA [31] 2008 randomized, placebo-
controlled, double-blind
study




[32] 2010 randomized, placebo-
controlled, double-blind
study




[33] 2010 randomized, placebo-
controlled, double-blind
study
20 3 μg/kg b.i.d. for
10 days, i.v.
 
Table 1.Clinical studies of ghrelin
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; FD, functional
dyspepsia; ESRD, End-stage renal disease; THR, total hip replacement; OA, osteoarthritis
